DOCSLIB.ORG

Antimicrobial Resistance in Shigellosis, Cholera and Campylobacteriosis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Antimicrobial Resistance in Shigellosis, Cholera and Campylobacteriosis WHO/CDS/CSR/DRS/2001.8 Antimicrobial resistance in shigellosis, cholera and campylobacteriosis David A. Sack, Christine Lyke, Carol McLaughlin and Voravit Suwanvanichkij World Health Organization Department of Communicable Disease Surveillance and Response This document has been downloaded from the WHO/CSR Web site. The original cover pages and lists of participants are not included. See http://www.who.int/emc for more information. WHO/CDS/CSR/DRS/2001.8 ORIGINAL: ENGLISH DISTRIBUTION: GENERAL Antimicrobial resistance in shigellosis, cholera and campylobacteriosis David A. Sack, Christine Lyke, Carol McLaughlin and Voravit Suwanvanichkij Johns Hopkins University School of Hygiene and Public Health Baltimore, MD, United States of America World Health Organization A BACKGROUND DOCUMENT FOR THE WHOFOR GLOBAL CONTAINMENT STRATEGY OF ANTIMICROBIALRESISTANCE Acknowledgement The World Health Organization wishes to acknowledge the support of the United States Agency for Inter- national Development (USAID) in the production of this document. © World Health Organization 2001 This document is not a formal publication of the World Health Organization (WHO), and all rights are reserved by the Organiza- tion. The document may, however, be freely reviewed, abstracted, reproduced and translated, in part or in whole, but not for sale or for use in conjunction with commercial purposes. The views expressed in documents by named authors are solely the responsibility of those authors. The designations employed and the presentation of the material in this document, including tables and maps, do not imply the expression of any opinion whatsoever on the part of the secretariat of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. Designed by minimum graphics Printed in Switzerland WHO/CDS/CSR/DRS/2001.4 DRUG RESISTANC IN MALARIA Contents Summary of antimicrobial resistance in bacterial enteric pathogens 1 Interventions 2 Research 5 Review of Vibrio cholerae 8 Introduction 8 Microbiology 8 Transmission 9 Spectrum of illness 9 Disease incidence and trends 10 Regional resistance trends 11 Causes of resistance 14 The question of prophylaxis 17 Potential vaccines 17 Recommendations 18 Research priorities 19 Conclusion 20 Review of Shigella spp. 21 Introduction 21 Organisms and syndrome 21 Geographical distribution 22 Diagnosis and resistance detection 22 Pathogenesis 23 Therapy 23 Drug resistance and trends 25 Mechanisms of resistance 26 Intervention strategies and research needs 29 Conclusion 30 Review of Campylobacter jejuni 31 Introduction 31 Microbiology 31 Transmission 31 Spectrum of illness 32 Pathogenicity 33 Diagnosis and identification 34 Therapy 34 Antimicrobial resistance 35 Mechanisms of resistance development 38 Prevention 39 Intervention strategies 40 Conclusion 40 Conclusion 42 Bibliography 43 iii WHO/CDS/CSR/DRS/2001.8 ANTIMICROBIAL RESISTANCE IN SHIGELLOSIS, CHOLERA AND CAMPYLOBACTERIOSIS Summary of antimicrobial resistance in bacterial enteric pathogens Important enteric pathogens are becoming in- view was clearly incorrect, as resistant strains caused creasingly resistant to the major antibiotics that large epidemics in the United Republic of Tanza- are needed for optimal treatment of patients. The nia and Bangladesh in the late 1970s. Since then, three bacterial pathogens chosen for this review antibiotic resistance patterns have varied widely at (Vibrio cholerae, Shigella spp. and Campylo- different times and in different places, with multi- bacter jejuni) are very different from one another. ply antibiotic-resistant strains commonly found They cause quite different clinical syndromes; during epidemics. Unlike Shigella spp., however, their ecology, epidemiology and modes of trans- strains of V. cholerae frequently revert to antibiotic mission are distinct; and they are widely sepa- sensitivity. An example of reversion to resistance rated genetically. The fact that three such occurred with the new serotype, O139. Initially all different organisms are becoming increasingly strains of this new pathogen were resistant to antibiotic-resistant underlines the pervasiveness trimethoprim, but now most strains are sensitive. of the pressures that lead to the emergence and The reversion to sensitivity is probably best ex- spread of resistance. plained by the ecology of the vibrio. Being prima- rily an environmental water organism and only Shigella spp. show a pattern of steadily increasing secondarily a human pathogen, it must adapt to resistance to antibiotics. Among the four species, the conditions of its primary ecological niche, in S. dysenteriae 1 (Shiga’s bacillus) is generally the first which antibiotic resistance does not provide a to develop resistance to a new antibiotic, but then major benefit to the bacteria. the other Shigella species follow. Rarely does sus- Campylobacter jejuni has yet another ecological ceptibility reappear once resistant strains have niche, being primarily adapted to animals, in par- become endemic in a region. In order to ensure ticular to birds. The industrialization of poultry appropriate treatment, continual surveillance is production has provided an environment in which required to determine which antibiotics are still resistant bacteria flourish, and these strains are then active. This strategy of “trying to keep one step easily spread to humans. Especially worrisome is ahead” implicates the continual development and the routine use of fluoroquinolones for growth pro- testing of new antibiotics, which inevitably are more motion in poultry. Generally, antibiotics used in expensive. After extensive use of these new antibi- animals should be different from those used for otics, their prices do fall, but not to the level of the humans, but in this instance an antibiotic class with older, previously effective antibiotics. In this race unique benefits for humans is, for economic rea- between the development of new antibiotics by the sons, being used in animals, with resulting loss of pharmaceutical industry and the development of its effectiveness for treating human disease. This resistance in Shigella, it seems that the bacteria are would seem to be a matter for government regula- winning, and we face the prospect of having no tion. However, the difficulties are illustrated by the effective antibiotics for future epidemics of shigel- example of the United States of America, where losis. Expecting the pharmaceutical industry to different agencies regulate drugs for human and develop a novel and cost-effective antibiotic every animal use. The loss of the fluoroquinolones as few years is unrealistic over the long term. effective therapy for C. jejuni infections means that Vibrio cholerae, the agent that causes cholera, has ciprofloxacin will no longer be efficacious in the a much different history of antibiotic resistance. syndromic treatment of dysentery. A question that For many years it was thought that cholera epi- is not yet answered is the extent to which the demics caused by antibiotic-resistant strains were genetic determinants of fluoroquinolone resistance unlikely to occur because the bacteria seemed to can be transferred from C. jejuni to other enteric lack the ability to retain resistance plasmids. This and nonenteric bacteria. If this were to occur, the 1 ANTIMICROBIAL RESISTANCE IN SHIGELLOSIS, CHOLERA AND CAMPYLOBACTERIOSIS WHO/CDS/CSR/DRS/2001.8 spread of resistance originating in antibiotic-treated Factors involved in the emergence animals would represent an even more serious threat. of antibiotic resistance Among the common bacterial infectious agents, With all three organisms, the primary factor is the Neisseria gonorrheae and C. jejuni, which were once overuse of antibiotics; i.e. antibiotic pressure selects generally sensitive to most antibiotics, are now for resistant strains. Antibiotic pressure may be ex- becoming increasingly resistant to ciprofloxacin. erted directly (e.g. use of an antibiotic for shigello- sis to which the bacteria are resistant, thus favouring Clinical consequences of resistance the very bacteria one is attempting to eliminate). However, antibiotic pressure on an organism may The clinical consequences of antibiotic resistance occur indirectly, i.e. from using the antibiotics for vary among the three bacterial diarrhoea agents. entirely different reasons. Examples of inappropri- For shigellosis, antibiotics are the primary treat- ate uses of antibiotics that exert selective pressure ment. Patients treated with an ineffective antibi- for resistance in various bacteria are: administering otic may have more complications than if they had them to patients who have viral upper respiratory not been treated, because the antibiotic is likely to tract infections; feeding them to farm animals to affect the normal intestinal flora, thus actually enhance their growth. favouring the growth of the resistant shigella. In treating cholera, antibiotics have been shown to reduce the duration of illness and the fluid loss, Relationship between
Load more

Recommended publications
  • Shigella Infection - Factsheet
    Shigella Infection - Factsheet What is Shigellosis? How common is it? Shigellosis is an infectious disease caused by a group of bacteria (germs) called Shigella. It’s also known as bacillary dysentery. There are four main types of Shigella germ but Shigella sonnei is by far the commonest cause of this illness in the UK. Most cases of the other types are usually brought in from abroad. How is Shigellosis caught? Shigella is not known to be found in animals so it always passes from one infected person to the next, though the route may be indirect. Here are some possible ways in which you can get infected: • Shigella germs are present in the stools of infected persons while they are ill and for a week or two afterwards. Most Shigella infections are the result of germs passing from stools or soiled fingers of one person to the mouth of another person. This happens when basic hygiene and hand washing habits are inadequate, such as in young toddlers who are not yet fully toilet trained. Family members and playmates of such children are at high risk of becoming infected. • Shigellosis can be acquired from someone who is infected but has no symptoms. • Shigellosis may be picked up from eating contaminated food, which may look and smell normal. Food may become contaminated by infected food handlers who do not wash their hands properly after using the toilet. They should report sick and avoid handling food if they are ill but they may not always have symptoms. • Vegetables can become contaminated if they are harvested from a field with sewage in it.
    [Show full text]
  • Succession and Persistence of Microbial Communities and Antimicrobial Resistance Genes Associated with International Space Stati
    Singh et al. Microbiome (2018) 6:204 https://doi.org/10.1186/s40168-018-0585-2 RESEARCH Open Access Succession and persistence of microbial communities and antimicrobial resistance genes associated with International Space Station environmental surfaces Nitin Kumar Singh1, Jason M. Wood1, Fathi Karouia2,3 and Kasthuri Venkateswaran1* Abstract Background: The International Space Station (ISS) is an ideal test bed for studying the effects of microbial persistence and succession on a closed system during long space flight. Culture-based analyses, targeted gene-based amplicon sequencing (bacteriome, mycobiome, and resistome), and shotgun metagenomics approaches have previously been performed on ISS environmental sample sets using whole genome amplification (WGA). However, this is the first study reporting on the metagenomes sampled from ISS environmental surfaces without the use of WGA. Metagenome sequences generated from eight defined ISS environmental locations in three consecutive flights were analyzed to assess the succession and persistence of microbial communities, their antimicrobial resistance (AMR) profiles, and virulence properties. Metagenomic sequences were produced from the samples treated with propidium monoazide (PMA) to measure intact microorganisms. Results: The intact microbial communities detected in Flight 1 and Flight 2 samples were significantly more similar to each other than to Flight 3 samples. Among 318 microbial species detected, 46 species constituting 18 genera were common in all flight samples. Risk group or biosafety level 2 microorganisms that persisted among all three flights were Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, Salmonella enterica, Shigella sonnei, Staphylococcus aureus, Yersinia frederiksenii,andAspergillus lentulus.EventhoughRhodotorula and Pantoea dominated the ISS microbiome, Pantoea exhibited succession and persistence. K. pneumoniae persisted in one location (US Node 1) of all three flights and might have spread to six out of the eight locations sampled on Flight 3.
    [Show full text]
  • Recognizing and Treating New and Emerging Infections Encountered in Everyday Practice
    Recognizing and treating new and emerging infections encountered in everyday practice STEVEN M. GORDON, MD NFECTIOUS DISEASES, pre- MiikWirj:« Although infectious diseases were once considered a dicted earlier in this cen- diminishing threat, new pathogens are constantly challenging tury to be eliminated as a the health care system. This article reviews the clinical presen- public health problem, re- tation, diagnosis, and treatment of seven emerging infections I main the chief cause of death that primary care physicians are likely to encounter. worldwide and a significant cause of death and morbidity in i Parvovirus B19 attacks erythrocyte precursors; the United States.1 Challenging infection is usually benign and self-limiting but can cause the US public health system are aplastic crises in patients with chronic hemolytic disorders. several newly identified patho- Hemorrhagic colitis due to Escherichia coli 0157:H7 infection gens (eg, human immunodefi- can lead to the hemolytic-uremic syndrome, especially in chil- ciency virus [HIV], Escherichia dren; it also can cause thrombotic thrombocytopenia purpura. coli 0157:H7, hepatitis C) and a Chlamydia pneumoniae causes a mild pneumonia that resem- resurgence of old diseases pre- bles mycoplasmal pneumonia. Bacillary angiomatosis primar- sumed to be under control (eg, ily affects immunocompromised patients, especially those tuberculosis, syphilis). Further, infected with human immunodeficiency virus (HIV). At least multiple-drug resistance in two organisms can cause bacillary angiomatosis: Bartonella hense- strains of pneumococci, gono- lae and Bartonella quintana. Hantavirus pulmonary syndrome cocci, enterococci, staphylo- is spread by exposure to the droppings of infected rodents. cocci, salmonella, and mycobac- Contrary to previous thought, HIV continues to replicate teria undermines efforts to throughout the course of the illness and does not have a latency control the diseases they cause.2 phase.
    [Show full text]
  • Know Your Abcs: a Quick Guide to Reportable Infectious Diseases in Ohio
    Know Your ABCs: A Quick Guide to Reportable Infectious Diseases in Ohio From the Ohio Administrative Code Chapter 3701-3; Effective August 1, 2019 Class A: Diseases of major public health concern because of the severity of disease or potential for epidemic spread – report immediately via telephone upon recognition that a case, a suspected case, or a positive laboratory result exists. • Anthrax • Measles • Rubella (not congenital) • Viral hemorrhagic fever • Botulism, foodborne • Meningococcal disease • Severe acute respiratory (VHF), including Ebola virus • Cholera • Middle East Respiratory syndrome (SARS) disease, Lassa fever, Marburg • Diphtheria Syndrome (MERS) • Smallpox hemorrhagic fever, and • Influenza A – novel virus • Plague • Tularemia Crimean-Congo hemorrhagic infection • Rabies, human fever Any unexpected pattern of cases, suspected cases, deaths or increased incidence of any other disease of major public health concern, because of the severity of disease or potential for epidemic spread, which may indicate a newly recognized infectious agent, outbreak, epidemic, related public health hazard or act of bioterrorism. Class B: Disease of public health concern needing timely response because of potential for epidemic spread – report by the end of the next business day after the existence of a case, a suspected case, or a positive laboratory result is known. • Amebiasis • Carbapenemase-producing • Hepatitis B (perinatal) • Salmonellosis • Arboviral neuroinvasive and carbapenem-resistant • Hepatitis C (non-perinatal) • Shigellosis
    [Show full text]
  • E. Coli: Serotypes Other Than O157:H7 Prepared by Zuber Mulla, BA, MSPH DOH, Regional Epidemiologist
    E. coli: Serotypes other than O157:H7 Prepared by Zuber Mulla, BA, MSPH DOH, Regional Epidemiologist Escherichia coli (E. coli) is the predominant nonpathogenic facultative flora of the human intestine [1]. However, several strains of E. coli have developed the ability to cause disease in humans. Strains of E. coli that cause gastroenteritis in humans can be grouped into six categories: enteroaggregative (EAEC), enterohemorrhagic (EHEC), enteroinvasive (EIEC), enteropathogenic (EPEC), enterotoxigenic (ETEC), and diffuse adherent (DAEC). Pathogenic E. coli are serotyped on the basis of their O (somatic), H (flagellar), and K (capsular) surface antigen profiles [1]. Each of the six categories listed above has a different pathogenesis and comprises a different set of O:H serotypes [2]. In Florida, gastrointestinal illness caused by E. coli is reportable in two categories: E. coli O157:H7 or E. coli, other. In 1997, 52 cases of E. coli O157:H7 and seven cases of E. coli, other (known serotype), were reported to the Florida Department of Health [3]. Enteroaggregative E. coli (EAEC) - EAEC has been associated with persistent diarrhea (>14 days), especially in developing countries [1]. The diarrhea is usually watery, secretory and not accompanied by fever or vomiting [1]. The incubation period has been estimated to be 20 to 48 hours [2]. Enterohemorrhagic E. coli (EHEC) - While the main EHEC serotype is E. coli O157:H7 (see July 24, 1998, issue of the “Epi Update”), other serotypes such as O111:H8 and O104:H21 are diarrheogenic in humans [2]. EHEC excrete potent toxins called verotoxins or Shiga toxins (so called because of their close resemblance to the Shiga toxin of Shigella dysenteriae 1This group of organisms is often referred to as Shiga toxin-producing E.
    [Show full text]
  • Communicable Diseases Weekly Report
    Communicable Diseases Weekly Report Week 08, 21 February to 27 February 2021 In summary, we report: • Chancroid – one new case in a returned traveller • Rodent-borne disease risks • Novel coronavirus 2019 (COVID-19) • Summary of notifiable conditions activity in NSW For further information see NSW Health infectious diseases page. This includes links to other NSW Health infectious disease surveillance reports and a diseases data page for a range of notifiable infectious diseases. Chancroid One case of chancroid was notified this reporting week in a traveller returning from overseas. Chancroid is an acute sexually transmitted bacterial infection that causes painful genital ulcers. The condition is now rarely seen in Australia and only one other case has been notified in NSW during the past decade. Although the incidence of chancroid is decreasing globally, it is still reported in some regions within Africa, Asia, the Caribbean and South Pacific. Chancroid genital ulcer disease is a known risk factor for the transmission of HIV. The bacterium that causes chancroid, Haemophilus ducreyi, is usually transmitted through anal, oral, or vaginal sex with an infected person. After infection, one or more ulcers (sores) develop on the genitals or around the anus. Non-genital skin infections have also been reported globally, through non-sexual skin-to-skin contact with an infected person. The ulcers are usually painful, but rarely can be asymptomatic. Swelling in the groin (due to enlarged painful lymph nodes that can liquify and develop into buboes) can also occur. Other symptoms may include pain during sexual intercourse or while urinating. An infected person can spread the infection from their genital region to other parts of their body.
    [Show full text]
  • Annual Summary of Communicable Disease Reported to MDH, 2003
    MINNESOTA DEPARTMENT OF HEALTH DISEASE CONTROL N EWSLETTER Volume 32, Number 4 (pages 33-52) July/August 2004 Annual Summary of Communicable Diseases Reported to the Minnesota Department of Health, 2003 Introduction Minnesota Government Data Practices do not appear in Table 2 because the Assessment is a core public health Act (Section 13.38). Provisions of the influenza surveillance system is based function. Surveillance for communi- Health Insurance Portability and on reported outbreaks rather than on cable diseases is one type of ongoing Accountability Act (HIPAA) allow for individual cases. assessment activity. Epidemiologic routine communicable disease report- surveillance is the systematic collec- ing without patient authorization. Incidence rates in this report were tion, analysis, and dissemination of calculated using disease-specific health data for the planning, implemen- Since April 1995, MDH has participated numerator data collected by MDH and a tation, and evaluation of public health as one of the Emerging Infections standardized set of denominator data programs. The Minnesota Department Program (EIP) sites funded by the derived from U.S. Census data. of Health (MDH) collects disease Centers for Disease Control and Disease incidence may be categorized surveillance information on certain Prevention (CDC) and, through this as occurring within the seven-county communicable diseases for the program, has implemented active Twin Cities metropolitan area (Twin purposes of determining disease hospital- and laboratory-based surveil- Cities metropolitan area) or outside of it impact, assessing trends in disease lance for several conditions, including (Greater Minnesota). occurrence, characterizing affected selected invasive bacterial diseases populations, prioritizing disease control and food-borne diseases. Anaplasmosis efforts, and evaluating disease preven- Human anaplasmosis (HA) is the new tion strategies.
    [Show full text]
  • Zoonotic Diseases Fact Sheet
    ZOONOTIC DISEASES FACT SHEET s e ion ecie s n t n p is ms n e e s tio s g s m to a a o u t Rang s p t tme to e th n s n m c a s a ra y a re ho Di P Ge Ho T S Incub F T P Brucella (B. Infected animals Skin or mucous membrane High and protracted (extended) fever. 1-15 weeks Most commonly Antibiotic melitensis, B. (swine, cattle, goats, contact with infected Infection affects bone, heart, reported U.S. combination: abortus, B. suis, B. sheep, dogs) animals, their blood, tissue, gallbladder, kidney, spleen, and laboratory-associated streptomycina, Brucellosis* Bacteria canis ) and other body fluids causes highly disseminated lesions bacterial infection in tetracycline, and and abscess man sulfonamides Salmonella (S. Domestic (dogs, cats, Direct contact as well as Mild gastroenteritiis (diarrhea) to high 6 hours to 3 Fatality rate of 5-10% Antibiotic cholera-suis, S. monkeys, rodents, indirect consumption fever, severe headache, and spleen days combination: enteriditis, S. labor-atory rodents, (eggs, food vehicles using enlargement. May lead to focal chloramphenicol, typhymurium, S. rep-tiles [especially eggs, etc.). Human to infection in any organ or tissue of the neomycin, ampicillin Salmonellosis Bacteria typhi) turtles], chickens and human transmission also body) fish) and herd animals possible (cattle, chickens, pigs) All Shigella species Captive non-human Oral-fecal route Ranges from asymptomatic carrier to Varies by Highly infective. Low Intravenous fluids primates severe bacillary dysentery with high species. 16 number of organisms and electrolytes, fevers, weakness, severe abdominal hours to 7 capable of causing Antibiotics: ampicillin, cramps, prostration, edema of the days.
    [Show full text]
  • Communicable Diseases Communiqué DECEMBER 2012, Vol
    Communicable Diseases Communiqué DECEMBER 2012, Vol. 11(12) CONTENTS Shigellosis outbreak 1 Rabies 2 Trypanosomiasis 3 Influenza 4 Beyond our Borders 5 Shigellosis Outbreak in Nelson Mandela Bay Health District, Eastern Cape Province An NHLS pathologist based in Port Elizabeth (Nelson isolated from both blood culture and stool in a 2- Mandela Bay Health District, Eastern Cape Province) year-old child with severe bloody diarrhoea and noticed a sudden marked increase in the number of fever. There has been one fatal case to date (a 76- shigellosis cases at a provincial public hospital and year-old female who presented with bloody primary health care clinic in the district during the diarrhoea and dehydration). last week of November 2012. This was reported to the National Outbreak Unit (NICD-NHLS and Of the Shigella spp. isolates referred to the Centre National Department of Health) which prompted for Enteric Diseases (NICD-NHLS) for further further investigation. characterisation, 11 have been tested to date and all are Shigella flexneri 1b. Twelve laboratory-confirmed cases of S. flexneri had been reported between 23 and 26 November Humans and other large primates are the only 2012; by 3 December 2012 the number of natural reservoirs of Shigella spp. Person-to-person laboratory-confirmed cases had risen to 24 (21 of spread is the commonest mode of transmission, but whom had severe disease necessitating hospital infection and outbreaks can also be caused by admission). Although cases were identified in both contaminated food or water. Shigellosis is one of public and private healthcare facilities in the district, the most communicable of the bacterial causes of the majority were resident in the Kwazakhele area diarrhoea, since a low dose of organisms readily and shared no other common risk exposures.
    [Show full text]
  • Identification of Bordetella Spp. in Respiratory Specimens From
    504 Clinical Microbiology and Infection, Volume 14 Number 5, May 2008 isolates of extended-spectrum-beta-lactamase-producing Original Submission: 27 October 2007; Revised Sub- Shigella sonnei. Ann Trop Med Parasitol 2007; 101: 511–517. mission: 5 December 2007; Accepted: 19 December 21. Rice LB. Controlling antibiotic resistance in the ICU: 2007 different bacteria, different strategies. Cleve Clin J Med 2003; 70: 793–800. Clin Microbiol Infect 2008; 14: 504–506 22. Boyd DA, Tyler S, Christianson S et al. Complete nucleo- 10.1111/j.1469-0691.2008.01968.x tide sequence of a 92-kilobase plasmid harbouring the CTX-M-15 extended spectrum b-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada. Cystic fibrosis (CF) is an autosomal recessive Antimicrob Agents Chemother 2004; 48: 3758–3764. disease, characterised by defective chloride ion channels that result in multi-organ dysfunction, most notably affecting the respiratory tract. The RESEARCH NOTE alteration in the pulmonary environment is asso- ciated with increased susceptibility to bacterial infection. Recent advances in bacterial taxonomy and improved microbial identification systems Identification of Bordetella spp. in have led to an increasing recognition of the respiratory specimens from individuals diversity of bacterial species involved in CF lung with cystic fibrosis infection. Many such species are opportunistic T. Spilker, A. A. Liwienski and J. J. LiPuma human pathogens, some of which are rarely found in other human infections [1]. Processing Department of Pediatrics and Communicable of CF respiratory cultures therefore employs Diseases, University of Michigan Medical selective media and focuses on detection of School, Ann Arbor, MI, USA uncommon human pathogens.
    [Show full text]
  • Contamination of Currency Notes with Kanamycin Resistant Shigella Flexneri
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.07.982017; this version posted March 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Contamination of Currency Notes with Kanamycin Resistant Shigella flexneri Ebrahim Mohammed Al-Hajj1*, Malik Suliman Mohamed2,3, Noha A. Abd Alfadil4, Hisham N. Altayb5, Abeer Babiker Idris6, Salah-Eldin El-Zaki7 and Mohamed A. Hassan8,9 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan 2 Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, Kingdom of Saudi Arabia 3Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan. 4 Department of Pharmaceutical Microbiology, Faculty of Pharmacy, University of Alneelain, Khartoum, Sudan. 5 Biochemistry department, College of sciences, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia. 6 Department of Medical Microbiology, Faculty of Medical Laboratory Sciences, University of Khartoum, Khartoum, Sudan 7 Department of Epidemiology, Molecular Epidemiology Laboratory, Tropical Medicine Research Institute, Khartoum, Sudan. 8 Applied Bioinformatics Center, Africa City of Technology, Khartoum, Sudan. 9 Department of Bioinformatics, DETAGEN Genetic Diagnostics Center, Kayseri, Turkey *To whom correspondence should be addressed Ebrahim Mohammed Al-Hajj Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan.Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.03.07.982017; this version posted March 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • 1 Is Helicobacter Pylori Good for You?
    University of Maryland School of Medicine A Third Century Is Helicobacter pylori Good for You? To Treat or Not to Treat, That is the Question Steven J. Czinn, M.D. Professor and Chair University of Maryland School of Medicine Department of Pediatrics Baltimore, Maryland America’s Oldest Public Medical School - USA Where Discovery Transforms Medicine Learning Objectives Disclosure • To demonstrate that H. pylori is responsible In the past 12 months, I have had no relevant for a significant portion of gastroduodenal financial relationships with the disease. manufacturer(s) of any commercial product(s) • To understand how the host immune response and/or provider(s) of commercial services contributes to Helicobacter associated discussed in this CME activity. disease. • To understand how the host immune response to Helicobacter infection might prevent asthma. • To understand which patient populations should be treated. H. pylori is an Important Human Pathogen World-Wide Prevalence of H. pylori • H. pylori is a gram negative microaerophilic bacterium that selectively colonizes the stomach. 70% 80% • It infects about 50% of the world’s population. 30% 70% 30% 50% • It is classically considered a non-invasive organism, 40% 50% 70% 70% • There is a vigorous innate and adaptive immune 70% 90% response and inflammation that is Th1 predominant 70% and includes (chronic) lymphocyte and (active) 90% 80% 80% 70% neutrophil components. 20% • Despite this response the bacterium generally persists for the life of the host. Marshall, 1995 JAMA 274:1064 1 Natural History of H. pylori infection Eradicating H. pylori Treats or Prevents: Colon Gastric cancer??? Initial infection (in childhood) Adenocarcinoma Nonulcer Chronic gastritis (universal) Dyspepsia H.
    [Show full text]